TLR1 and neoplasm: Interestingly, systemic administration of a synthetic BLP, a TLR1/TLR2 agonist, to mice with established lung carcinoma, melanoma, or leukemia, led to tumor regression and a long-lasting protective response against tumor re-challenge (66).